Shiladitya Sengupta, Professor of Medicine at Harvard Medical School, shared on LinkedIn:
“On Wednesday, we presented our first set of clinical data from Alyssum Therapeutics at the EORTC-NNCI-AACR triple meeting at Barcelona.
Our clinical abstract was picked as the first plenary talk at the meeting- such an honor. This the the first drug (first in class CMTR2 inhibitor) that converts cold tumors into hot and activates a B cell-driven immune response against solid tumors.
Patients who had progressed within 19-20 weeks on Pembro or Nivo have been on treatment on AT-1965 for over 40 weeks (at 4-7th line treatment in patients with advanced sarcomas, breast, pancreatic cancer, etc).
96% of the patients exhibited increased absolute lymphocyte counts, consistent with the mechanism of action, with increased B cells in the tumor.
It is an honor to partner with patients as we advance the first ‘keytruda’ of B cells in cancer IO!”
You can also read: